Harbin Medisan Pharmaceutical Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.64, indicating a moderate level of leverage. However, the liquidity position is concerning, as the current ratio is 0.87, which is below 1, suggesting that the company may struggle to meet its short-term obligations. The negative operating cash flow of -36,250,160 CNY and free cash flow of -556,883,220 CNY further highlight the company's liquidity challenges. Profitability metrics are severely negative, with a return on equity of -0.1916 and a return on assets of -0.0983, both of which are well below industry norms. The company reported a net loss of -339,625,470 CNY, and its operating income was also negative at -351,422,370 CNY, indicating significant operational inefficiencies. The company's revenue is not segmented by product or geographic region in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the company's financial performance suggests that it may be facing challenges in maintaining consistent revenue growth. The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or outlooks. The negative operating and free cash flows, combined with the net loss, suggest that the company may need to address its operational performance to achieve sustainable growth. The company's risk profile is marked by medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential financial instability. The company's negative operating cash flow and free cash flow also contribute to the liquidity risk. Recent events and filings have not been disclosed in the available data, so it is not possible to provide specific information on recent company developments.